Novavax Stock Forecast, Price & News

Novavax (NASDAQ:NVAX) Frequently Asked Questions

Is Novavax a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax or view top-rated stocks.

How has Novavax's stock price been impacted by Coronavirus (COVID-19)?

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVAX stock has increased by 1,973.9% and is now trading at $217.97.
View which stocks have been most impacted by COVID-19.

Are investors shorting Novavax?

Novavax saw a increase in short interest in October. As of October 29th, there was short interest totaling 8,240,000 shares, an increase of 33.8% from the October 14th total of 6,160,000 shares. Based on an average daily trading volume, of 5,400,000 shares, the short-interest ratio is presently 1.5 days. Currently, 11.2% of the company's stock are sold short.
View Novavax's Short Interest.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Novavax.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($4.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.04) by $0.27. The biopharmaceutical company earned $178.80 million during the quarter, compared to analysts' expectations of $347.34 million. Novavax had a negative net margin of 89.31% and a negative trailing twelve-month return on equity of 149.66%. The business's revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($3.21) earnings per share.
View Novavax's earnings history.

When did Novavax's stock split? How did Novavax's stock split work?

Shares of Novavax reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for NVAX?

6 equities research analysts have issued 12 month price objectives for Novavax's stock. Their forecasts range from $161.00 to $294.00. On average, they anticipate Novavax's stock price to reach $249.60 in the next year. This suggests a possible upside of 14.5% from the stock's current price.
View analysts' price targets for Novavax or view top-rated stocks among Wall Street analysts.

Who are Novavax's key executives?

Novavax's management team includes the following people:

• Stanley C. Erck, President, Chief Executive Officer & Director (LinkedIn Profile)
• Richard Crowley, Chief Operating Officer & Executive Vice President
• James Patrick Kelly, Chief Financial Officer, Treasurer & Executive VP
• Gregory M. Glenn, President-Research & Development (LinkedIn Profile)
• Filip Dubovsky, Chief Medical Officer & Executive Vice President

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Who are some of Novavax's key competitors?

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Incyte (INCY), Exact Sciences (EXAS), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of NVAX's competitors.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (2.77%), Capital World Investors (1.96%), Citadel Advisors LLC (0.00%), Franklin Resources Inc. (1.42%), Geode Capital Management LLC (1.27%) and Jane Street Group LLC (0.00%). Company insiders that own Novavax stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax.

Which major investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Wellington Management Group LLP, PEAK6 Investments LLC, Schroder Investment Management Group, Lombard Odier Asset Management Switzerland SA, Balyasny Asset Management LLC, Franklin Resources Inc., and Victory Capital Management Inc.. Company insiders that have sold Novavax company stock in the last year include David M Mott, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax or view top insider-selling stocks.

Which major investors are buying Novavax stock?

NVAX stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, IMC Chicago LLC, Lord Abbett & CO. LLC, Citadel Advisors LLC, Connor Clark & Lunn Investment Management Ltd., Allianz Asset Management GmbH, Geode Capital Management LLC, and Worldquant Millennium Advisors LLC. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, James F Young, and Rachel K King.
View insider buying and selling activity for Novavax or or view top insider-buying stocks.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $217.97.

How much money does Novavax make?

Novavax has a market capitalization of $16.48 billion and generates $475.60 million in revenue each year. The biopharmaceutical company earns $-418.26 million in net income (profit) each year or ($14.81) on an earnings per share basis.

How many employees does Novavax have?

Novavax employs 375 workers across the globe.

When was Novavax founded?

Novavax was founded in 1987.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

Where are Novavax's headquarters?

Novavax is headquartered at 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at [email protected], or via fax at 240-268-2100.